Coronavirus company news summary – AstraZeneca signs a vaccine manufacturing deal with OxfordBiomedica – Novartis enters Covid-19 vaccine race

Allie Nawrat 29 May 2020 (Last Updated May 29th, 2020 09:34)

29 May 2020

AstraZeneca has entered into a one-year clinical and commercial supply agreement with Oxford Biomedica to manufacture its adenovirus vector-based Covid-19 vaccine candidate, AZD1222, which was developed by the University of Oxford researchers. The agreement will provide AstraZeneca with access to Oxford Biomedica’s 7,800m2 commercial manufacturing centre in Oxford.

PureTech Health has plans to conduct a clinical trial to assess LYT-100 (deupirfenidone) to treat serious respiratory complications that persist even after resolution of Covid-19 infection. Expected to start in the third quarter of this year, the trial will enrol about 150 non-critical patients with respiratory complications.

Novartis has signed a manufacturing deal with US researchers to produce a Covid-19 vaccine candidate, which is based on technology similar to that of the company’s gene therapy drug Zolgensma, according to Reuters. The researchers at Massachusetts General Hospital and Massachusetts Eye and Ear said that manufacturing will occur at Novartis’ gene therapy unit AveXis.

RNA therapeutics company Chimeron Bio has collaborated with George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID) to develop a Covid-19 vaccine candidate. The vaccine will be developed using Chimeron Bio’s ChaESARTM self-amplifying RNA technology, which is designed to deliver immunogenic viral genes to trigger rapid and sustained immune response.